This study evaluates the preclinical efficacy and safety of HPN328, a trispecific T cell–activating protein construct designed to target Delta-like ligand 3 (DLL3) on solid tumors. HPN328 aims to redirect T cells to DLL3-expressing cancer cells, promoting targeted tumor cell lysis.
HPN328 demonstrated potent and specific cytotoxicity against DLL3-expressing tumor cells in vitro and led to significant tumor regression in vivo without notable off-target effects. These results support the potential of HPN328 as a therapeutic agent for DLL3-positive malignancies.
The study utilized a humanized mouse model developed in collaboration with genOway. This model expresses human DLL3 and features a reconstituted human immune system, allowing for the assessment of HPN328's activity in an in vivo setting that closely mimics human tumor-immune interactions.
Oncology, Solid tumors, Immunotherapy, T cell engagement, Targeted therapy
Humanized mouse model, Human DLL3 expression, Reconstituted human immune system, In vivo efficacy assessment, Tumor-immune interaction modeling
From model design to experimental results
Tailor-made solutions adapted to scientific questions
Comprehensive dataset package
Generated with biopharma partners and in-house
Scientific follow-up and advice along the project
Collaborative approach for problem solving and development of innovative models
Breeding facilities in US and Europe
Certified health status from professional breeders
